Difficult asthma: Assessment and management, part 2

Allergy and Asthma Proceedings

Volumn 33, Issue 4, 2012, Pages 313-323

  Fanta, Christopher H ^a,b   Long, Aidan A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZITHROMYCIN; BECLOMETASONE; BRONCHODILATING AGENT; BUDESONIDE; CLARITHROMYCIN; CYCLOSPORIN; ETANERCEPT; FLUTICASONE; IMATINIB; IMMUNOGLOBULIN E; IPRATROPIUM BROMIDE; ITRACONAZOLE; LEBRIKIZUMAB; MEPOLIZUMAB; METHOTREXATE; OMALIZUMAB; PLACEBO; PREDNISONE; RESLIZUMAB; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; VITAMIN D; VORICONAZOLE; ZILEUTON;

ADRENAL INSUFFICIENCY; AIRWAY OBSTRUCTION; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANAPHYLAXIS; ANTIBIOTIC THERAPY; ASTHMA; ATROPHY; BRONCHIAL THERMOPLASTY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLUSTER ANALYSIS; CONFERENCE PAPER; CUSHING SYNDROME; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHILIA; EOSINOPHILIC ASTHMA; FORCED EXPIRATORY VOLUME; HEARING LOSS; HEART INFARCTION; HEAT TREATMENT; HUMAN; HYPERTENSION; HYPOPIGMENTATION; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY FAILURE; LIVER TOXICITY; LOW DRUG DOSE; LUNG FUNCTION; MORTALITY; NEBULIZATION; NEBULIZER; NEOPLASM; NEPHROTOXICITY; QUALITY OF LIFE; STEROID THERAPY; STROKE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VITAMIN BLOOD LEVEL; XEROSTOMIA;

ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; BRONCHI; BRONCHOSCOPY; DISEASE MANAGEMENT; HUMANS; SYMPTOM ASSESSMENT;

EID: 84864740836     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2012.33.3577     Document Type: Conference Paper

References (70)

1. Long AA, and Fanta CH. Difficult asthma: Assessment and management, Part 1. Allergy Asthma Proc 33:305-312, 2012.
2. Dahlèn B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 157:1187-1194, 1998.
3. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 341:1966 -1973, 1999.
4. Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonR1 expression. J Allergy Clin Immunol 112:1147-1154, 2003. (Pubitemid 37550008)
5. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: A randomized trial. Ann Intern Med 154:573-582, 2011.
6. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60:309 -316, 2005.
7. Verma P, Randhawa I, and Klaustermeyer WB. Clinical efficacy of omalizumab in an elderly veteran population with severe asthma. Allergy Asthma Proc 32:346 -350, 2011.
8. Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 120: 1373-1377, 2007. (Pubitemid 350216610)
9. Cox L, Lieberman P, Wallace D, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report (Letter to the Editor). J Allergy Clin Immunol 128:210 -212, 2011.
10. Chowdhury BA. U.S. Food and Drug Administration Meeting of the Pulmonary-Allergy Drugs Advisory Committee, November 18, 2009. Available online at www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ Pulmonary-AllergyDrugsAdvisoryCommittee/UCM194068.pdf; accessed November 25, 2011.
11. Long AA, Fish JE, Rahmaoui A, et al. Baseline characteristics of patients enrolled in EXCELS: A cohort study. Ann Allergy Asthma Immunol 103:212-219, 2009.
12. Long AA, Eisner MD, Miller MK, et al. Omalizumab and the incidence of malignancy: Interim results from the EXCELS study. Am J Respir Crit Care Med 183:A4492, 2011 (Abs).
13. FDA Safety Alerts for Human Medical Products. Omalizumab (marketed as Xolair)-Early communication about an ongoing safety review. Available online at www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm172406.htm; accessed November 25, 2011.
14. Cox G, Thomson NC, Rubin AS, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med 356:1327-1337, 2007. (Pubitemid 46513298)
15. Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: A multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 181:116 -124, 2010.
16. Thomson NC, Rubin AS, Niven RM, et al. Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial. BMC Pulm Med 11:8, 2011.
17. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda, MD. National Heart, Lung, and Blood Institute, August 2007. National Institutes of Health (NIH) Publication No. 07-4051. Available online at www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf; accessed November 25, 2011.
18. The Global Initiative for Asthma. Global Strategy for asthma management and prevention, Global Initiative for Asthma (GINA) 2010. Available online at www.ginasthma.org; accessed May 5, 2012.
19. Leach C, Colice GL, and Luskin A. Particle size of inhaled corticosteroids: Does it matter? J Allergy Clin Immunol 124:S88-S93, 2009.
20. Cumming RG, Mitchell P, and Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 337:8 -14, 1997.
21. Garbe E, LeLorier J, Boivin JF, and Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or openangle glaucoma. JAMA 277:722-727, 1997. (Pubitemid 27106224)
22. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 345:941-947, 2001.
23. Greening AP, Ind PW, Northfield M, and Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344:219-224, 1994. (Pubitemid 24229008)
24. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: Genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364:1505-1512, 2004. (Pubitemid 39410416)
25. Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): A genotypestratified, randomised, placebo-controlled, crossover trial. Lancet 374:1754 -1764, 2009.
26. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 363:1715-1726, 2010.
27. Singh S, Loke YK, and Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. JAMA 300:1439-1450, 2008.
28. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359:1543-1554, 2008.
29. Weinberger M, and Abu-Hasan M. Life-threatening asthma during treatment with salmeterol. N Engl J Med 355:852-853, 2006.
30. Hahn DL, Bukstein D, Luskin A, and Zeitz H. Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma. Ann Allergy Asthma Immunol 80:45-49, 1998. (Pubitemid 28086755)
31. Crosbie PA, and Woodhead MA. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 33:171-181, 2009.
32. Hahn DL, Plane MB, Mahdi OS, and Byrne GI. Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clin Trials 1(2):e11. (DOI: 10.1371/journal.pctr. 0010011.)
33. Kraft M, Cassell GH, Pak J, and Martin RJ. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: Effect of clarithromycin. Chest 121:1782-1178, 2002.
34. Sutherland ER, King TS, Icitovic N, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 126:747-753, 2010.
35. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365:689-698, 2011.
36. Lange NE, Litonjua A, Hawrylowicz CM, and Weiss S. Vitamin D, the immune system and asthma. Expert Rev Clin Immunol 5:693-702, 2009.
37. Brehm JM, Celedón JC, Soto-Quiros ME, et al. Serum vitamin D levels and markers of severity of childhood asthma in Costa Rica. Am J Respir Crit Care Med 179:765-771, 2009.
38. Camargo CA Jr, Rifas-Shiman SL, Litonjua AA, et al. Maternal intake of vitamina D during pregnancy and risk of recurrent wheeze in children at 3 y of age. Am J Clin Nutr 85:788 -795, 2007.
39. Brehm JM, Schuemann B, Fuhlbrigge AL, et al. Serum vitamin D levels and severe asthma exacerbations in the Childhood Management Program Study. J Allergy Clin Immunol 126:52-58, 2010.
40. Searing DA, Zhang Y, Murphy JR, et al. Decreased serum vitamin D levels in children with asthma are associated with increased corticosteroid usage. J Allergy Clin Immunol 125:995-1000, 2010.
41. Paul G, Brehm J, Alcorn JF, et al. Vitamin D and asthma. Am J Respir Crit Care Med 185:124-132, 2012.
42. Mullarkey MF, Blumenstein BA, Andrade WP, et al. Methotrexate in the treatment of corticosteroid-dependent asthma. N Engl J Med 318:603-607, 1988.
43. Aaron SD, Dales RE, and Pham B. Management of steroiddependent asthma with methotrexate: A meta-analysis of randomized clinical trials. Respir Med 92:1059-1065, 1998. (Pubitemid 28416838)
44. Davies H, Olson L, and Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2:CD000391, 2000.
45. Alexander AG, Barnes NC, and Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 339:324-328, 1992.
46. Lock SH, Kay AB, and Barnes NC. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 153:509-514, 1996. (Pubitemid 26051322)
47. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor α in refractory asthma. N Engl J Med 354:697-708, 2006. (Pubitemid 43247140)
48. Morjaria JB, Chauhan AJ, Babu KS, et al. The role of a soluble TNFα receptor fusion protein (etanercept) in corticosteroid refractory asthma: A double blind, randomized, placebo controlled trial. Thorax 63:584-591, 2008. (Pubitemid 351969250)
49. Holgate ST, Noonan M, Chanez P, et al. Efficacy and safety of etanercept in moderate-to-severe asthma: A randomized, controlled trial. Eur Respir J 37:1352-1359, 2011.
50. Ogirala RG, Sturm TM, Aldrich TK, et al. Single, high-dose intramuscular triamcinolone acetonide versus weekly oral methotrexate in life-threatening asthma: A double-blind study. Am J Respir Crit Care Med 152:1461-1466, 1995.
51. Mancinelli L, Navarro L, and Sharma OP. Intramuscular highdose triamcinolone acetonide in the treatment of severe chronic asthma. West J Med 157:322-329, 1997. (Pubitemid 27500485)
52. Tantisira KG, Lasky-Su J, Harada M, et al. Genomewide association between GLCCI1 and response to glucocortiocoid therapy in asthma. N Engl J Med 365:1173-1183, 2011.
53. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363:1991-2003, 2010.
54. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 181:315-323, 2010.
55. Fitzpatrick AM, Teague WG, Meyers DA, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol 127:382-389, 2011.
56. Lötvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 127:355-360, 2011.
57. Dykewicz MS, Greenberger PA, Patterson R, and Halwig JM. Natural history of asthma in patients requiring long-term systemic corticosteroids. Arch Intern Med 146:2369 -2372, 1986.
58. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 148:1447-1451, 1993. (Pubitemid 24002469)
59. Lee RU, and Stevenson DD. Aspirin-exacerbated respiratory disease: Evaluation and management. Allergy Asthma Immunol Res 3:3-10, 2011.
60. Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: Role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 113:101-108, 2004. (Pubitemid 38096168)
61. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 178:218-224, 2008.
62. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360:973-984, 2009.
63. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: A randomized, placebo-controlled study. Am J Respir Crit Care Med 184:1125-1132, 2011.
64. Patterson K, and Strek ME. Allergic bronchopulmonary aspergillosis. Proc Am Thorac Soc 7:237-244, 2010.
65. Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 342:756-762, 2000. (Pubitemid 30151919)
66. Sears MR. Lung function decline in asthma. Eur Respir J 30:411-413, 2007. (Pubitemid 351182061)
67. Bai TR, Vonk JM, Postma DS, and Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 30:452- 456, 2007.
68. Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR): A large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 92:32-39, 2004. (Pubitemid 38113629)
69. Marquette CH, Saulnier F, Leroy O, et al. Long-term prognosis of near-fatal asthma: A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. Am Rev Respir Dis 146:76-81, 1992.
70. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 365:1088 -1098, 2011.